Factor VIII concentrates in HIV-1-positive hemophiliacs--is pure better?

Haemostasis. 1992;22(1):25-31. doi: 10.1159/000216288.

Abstract

39 human immunodeficiency-virus-1 (HIV-1)-positive hemophiliacs who had been regularly treated with non-virus-inactivated intermediate-purity factor VIII concentrates were divided into two groups. Group A consisted of 21 patients with a CD4/CD8 cell ratio of less than 1.0 and group B of 18 patients with a CD4/CD8 cell ratio of greater than 1.0. All patients of group A were switched to a high-purity virus-inactivated factor VIII concentrate, whereas patients of group B continued to receive the intermediate-purity concentrate. There was no significant difference in the average decline of CD4 cells between the two groups during the observation period. 9 patients of group A and 4 patients of group B developed AIDS. 5 patients of group A but 11 patients of group B remained clinically asymptomatic. We conclude that the 15-fold increase in purity of the factor VIII concentrate had no apparent beneficial effect on the CD4 cell counts in this patient group.

Publication types

  • Comparative Study

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications
  • Acquired Immunodeficiency Syndrome / prevention & control
  • Adolescent
  • Adult
  • Blood Proteins / adverse effects
  • CD4-CD8 Ratio
  • Child
  • Cohort Studies
  • Factor VIII / standards
  • Factor VIII / therapeutic use*
  • Follow-Up Studies
  • HIV Infections / complications*
  • HIV-1*
  • Hemophilia A / complications
  • Hemophilia A / therapy*
  • Hot Temperature
  • Humans
  • Immune Tolerance
  • Male
  • Middle Aged

Substances

  • Blood Proteins
  • Factor VIII